Andrew R. Saik
Board Member
Milestone Pharmaceuticals Inc. (MIST)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Andrew R. Saik
Andrew R. Saik is recorded as Board Member at Milestone Pharmaceuticals Inc. (MIST). Milestone Pharmaceuticals Inc. reported in an 8-K filed June 12, 2025 that Andrew R. Saik was appointed director, effective June 10, 2025. Milestone Pharmaceuticals Inc. reported in an 8-K filed July 15, 2024 that Andrew R. Saik was appointed director, effective July 14, 2024.
“The Company’s shareholders elected the nominees below to the board of directors (the “Board”) each to hold office until the 2026 Annual Meeting of Shareholders, or until their successors are duly elected or appointed or until such directors’ earlier resignation or removal.”
“the Company increased the size of the Board of Directors (the "Board") to nine (9) directors and appointed Stuart M. Duty and Andrew R. Saik (collectively, the "Initial New Directors") to the Board to fill the resulting vacancies, each with a term expiring at the Company's 2024 annual meeting of shareholders (the "2024 Annual Meeting"), or until their earlier death, disability, resignation, disqualification, or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-01-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Milestone Pharmaceuticals Inc.
Other people whose current roles at this company are on record from its filings.
- Joseph Oliveto CEO, Board Member
- Amit Hasija CFO
- Jeffrey Nelson COO
- David Sandoval General Counsel
- Timothy Maness Chief Accounting Officer
- Andrew Saik Board Member
- Joeseph C. Papa Board Member
- Joseph C. Papa Board Member
- Lisa M. Giles Board Member
- Michael Tomsicek Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.